Revocation and Determination
of
Statement of Principles
concerning
ASTHMA
Veterans’ Entitlements Act 1986
1. The
Repatriation Medical Authority under subsection 196B(3) of the Veterans’
Entitlements Act 1986 (the Act):
(a) revokes Instrument No.60 of 1996 and
Instrument No.76 of 1997; and
(b) determines in its place the following
Statement of Principles.
Kind of injury, disease
or death
2. (a) This
Statement of Principles is about asthma and death from asthma.
(b)
For the purposes of this Statement
of Principles, “asthma” means a condition marked by increased
responsiveness of the bronchi to various stimuli manifested by recurrent
attacks of paroxysmal dyspnoea, with wheezing due to spasmodic contraction of
the bronchi which characteristically responds rapidly to bronchodilators. The
airflow obstruction may not be completely reversible. This definition includes
chronic airway obstruction due to asthma, and reactive airways dysfunction
syndrome.
Basis for determining the
factors
3. On
the sound medical-scientific evidence available, the Repatriation Medical
Authority is of the view that it is more probable than not that asthma and
death from asthma can be related to relevant service rendered by veterans
or members of the Forces.
Factors that must be
related to service
4. Subject
to clause 6, at least one of the factors set out in clause 5 must be related to
any relevant service rendered by the person.
Factors
5. The
factors that must exist before it can be said that, on the balance of
probabilities, asthma or death from asthma is connected with the
circumstances of a person’s relevant service are:
(a) for the first episode of
asthma only, being exposed to an occupational antigen within the 24 hours
before the clinical onset of asthma; or
(b)
for the first episode of asthma
only, being exposed to an antigenic stimulus causing asthma within the 24 hours
before the clinical onset of asthma; or
(c)
for reactive airways dysfunction
syndrome only, having an exposure to an agent as specified within the 24 hours
before the clinical onset of asthma; or
(d)
being
exposed to an antigenic stimulus or nonantigenic stimulus within the 24 hours
before the clinical worsening of asthma; or
(e)
suffering from gastro-oesophageal
reflux disease at the time of the clinical worsening of asthma; or
(f)
inability to obtain appropriate
clinical management for asthma.
Factors that apply only
to material contribution or aggravation
6. Paragraphs 5(d) to 5(f) apply only to material
contribution to, or aggravation of, asthma where the person’s asthma was
suffered or contracted before or during (but not arising out of) the person’s
relevant service; paragraph 8(1)(e), 9(1)(e) or 70(5)(d) of the Act refers.
Inclusion of Statements of Principles
7. In this Statement of Principles if a relevant factor applies
and that factor includes an injury or disease in respect of which there is a
Statement of Principles then the factors in that last mentioned Statement of
Principles apply in accordance with the terms of that Statement of Principles.
Other definitions
8.
For the purposes of this
Statement of Principles:
“an exposure to an agent
as specified” means an episode of
exposure by inhalation of an irritant gas, smoke, fume, or vapour that:
(a)
has been reported in a peer
reviewed medical or scientific publication to have caused reactive airways
dysfunction syndrome, as defined; and
(b)
resulted in acute toxic lower
respiratory tract effects that warranted immediate treatment;
“antigenic stimulus” means any substance which is capable of inducing a specific immune
response and of reacting with the products of that response, that is, with
specific antibody or specifically sensitised T-lymphocytes. Antigens may be
soluble substances such as toxins and foreign proteins, or particulate such as
bacteria and tissue cells;
“antigenic stimulus causing asthma” means an antigenic substance which has been reported in a peer reviewed
medical or scientific publication to precipitate the new onset of asthma after
exposure; where reported cases have been defined by the close temporal
relationship between exposure to an antigenic agent, and
(a)
significant related changes in
forced expiratory flow rate in one second;
(b)
significant related changes in
peak expiratory flow rate; or
(c)
positive response to inhalation
provocation testing with an agent to which the person is exposed;
“clinical worsening of asthma” means permanent worsening of asthma evidenced by:
(a) status
asthmaticus;
(b) an
asthmatic attack resulting in hypoxic damage (eg cerebral hypoxia);
(c) an
asthmatic attack leading to death; or
(d) an increase in maintenance
asthmatic medication due to the patient not being able to discontinue their
exposure to the stimulus (eg. beta blockers) causing a worsening of asthma
symptoms;
“death from asthma” in relation to a person includes death from a terminal event or
condition that was contributed to by the person’s asthma;
“gastro-oesophageal reflux disease” means the presence of regurgitation of gastric
content into the oesophagus together with resultant symptomatic and/or
histologic evidence of oesophageal inflammation;
“nonantigenic stimulus” means cold air, emotional stress, exercise, drugs
(including beta blockers), respiratory infection or inhaled irritants such as
ozone, sulphur dioxide, mustard gas, or smoke, including cigarette smoke;
“occupational antigen” means one of the following specific inhaled substances
present in the workplace which precipitate the new onset of asthma:
(a)
metal salts of platinum, chrome,
or nickel;
(b)
dusts from oak, western red cedar,
African maple, or ramin wood;
(c)
dusts or aerosols from cereal
grain, wheat flour, rye flour, the castor bean, green coffee bean, soybean,
buckwheat, latex, or hydrolysed gluten;
(d)
powdered forms of antibiotics,
piperazine hydrochloride, or cimetidine;
(e)
fumes or dusts from toluene
diisocyanate, methylene diphenyl diisocyanate, hexamethylene diisocyanate,
phthalic acid anhydride, trimellitic anhydride, hexahydrophthalic anhydride,
tetrahydrophthalic anhydride, himic anhydride, persulfate salts,
ethylenediamine, p-phenylenediamine, ethylene diamine, triethylene
tetramine, or reactive dyes: tartrazine; azoquinone; anthroquinone; methyl
blue; or black G-R;
(f)
dusts or vapours from biological
enzymes, subtilisin, aspergillus enzymes, trypsin, pancreatin, or laundry
detergents;
(g)
dusts or vapours from animal hair,
pelts, urine, serum and secretions, or crustaceans; or
(h)
insect dusts and secretions;
“reactive airways dysfunction syndrome” means an asthma-like condition satisfying the
following criteria:
(a)
a documented absence of preceding
asthma or other ongoing bronchial disorders;
(b)
onset of symptoms after a single
exposure incident or accident;
(c)
exposure to a gas, smoke, fume, or
vapour, with irritant properties, present in very high concentrations;
(d)
onset of symptoms within 24 hours
after the acute exposure, with persistence of symptoms for at least three
months;
(e)
symptoms simulate asthma;
(f)
presence of reversible airflow
obstruction on pulmonary function tests and/or the presence of nonspecific
bronchial hyperresponsiveness; and
(g)
other pulmonary diseases ruled
out;
“relevant
service” means:
(a) eligible
war service (other than operational service); or
(b) defence service (other than
hazardous service);
“terminal event” means the proximate or ultimate cause of death and
includes:
(a) pneumonia;
(b) respiratory failure;
(c) cardiac arrest;
(d) circulatory failure; or
(e)
cessation of brain function.
Application
9. This Instrument applies to all matters to which section 120B
of the Act applies.
Notes to Statement of Principles concerning asthma
(Instrument No. 86 of 2001)
The Statement of Principles concerning asthma (Instrument
No. 86 of 2001) in force under section 196B(3) of the Veterans’ Entitlements
Act 1986, as shown in this compilation is amended as indicated in the
Tables below.
Table
of Instruments
|
Title
|
Date of notification
in Gazette or FRLI registration
|
Date of
commencement
|
Application, saving or
transitional provisions
|
|
Statement
of Principles concerning asthma (Instrument No. 86 of 2001)
|
28 November 2001
(see Gazette 2001, No. GN47)
|
28 November 2001
|
|
|
Amendment
of Statement of Principles concerning asthma (Instrument No. 37 of 2004)
|
20 October 2004
(see Gazette 2004, No. G42)
|
20 October 2004
|
|
Table of Amendments
|
ad. = added or inserted am. = amended
rep. = repealed rs. = repealed and substituted
|
|
Provision affected
|
How affected
|
|
Paragraph 2(b) – ‘asthma’
|
rs. Instrument No.37 of 2004
|